Last update: March 2019
The usual starting dose for Praluent is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started
on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.
Time out of fridge1
Self or care-giver administered1
Patients (n = 200) agreed that the Praluent pen device was easy to use because the parts are clearly labelled and colour-coded (Figure 1)2
Although many patients requiring lipid lowering therapies are not experienced with self-injected medication, a real-world clinical study has demonstrated that the pre-filled pen device is well accepted by patients and healthcare practitioners2.
Figure 1. The Praluent pre-filled pen
Praluent Injection video
Watch this video to see how patients should inject themselves with the Praluent Pen
- Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/30956. Accessed March 2019.
- Roth EM, et al. Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels Clin Ther. 2015; 37:1945–1954.
- Praluent. Patient information leaflet. Available at https://www.medicines.org.uk/emc/PIL.30964.latest.pdf. Accessed August 2018.